RxDoctor Payments Data

Rachna Raman, MD

Internal Medicine · Mechanicsville, VANPI 1710183710

Payments from drug & device makers

$3,692in general payments, 2019–2025

Across 32 payments — averaging $115.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$2K
  • Exelixis Inc.$1K
  • Astellas Pharma US Inc$124
  • Caris MPI, Inc.$92
  • Seagen Inc.$73
  • Pfizer$65
  • plus $401 from 13 others

What the payments were for

  • Consulting fees$1,71347%
  • Speaking & faculty fees$1,22534%
  • Food & beverage$51114%
  • Education$2026%

General payments by program year

19
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,692 in reported general payments places this provider in the 85th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$98,542
Medicare patients
384
Services billed
889

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PomalystPomalidomide48$1,109,334
Lenalidomide47$682,252
ImbruvicaIbrutinib41$396,662
CalquenceAcalabrutinib Maleate30$387,743
CabometyxCabozantinib S-Malate15$357,328
TagrissoOsimertinib Mesylate13$334,403
RevlimidLenalidomide15$216,393
BrukinsaZanubrutinib12$83,119
XareltoRivaroxaban23$24,648
EliquisApixaban23$18,941
Abiraterone Acetate14$2,595
Anastrozole73$1,111
Letrozole43$1,094
Hydroxyurea36$674
Acyclovir30$619

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Pomalyst$35$1,109,33448 claims
AstraZenecaCalquence, Tagrisso$42$722,14643 claims
Exelixis Inc.Cabometyx$1,225$357,32815 claims
Beigene USA, Inc.Brukinsa$37$83,11912 claims
PfizerEliquis$65$18,94123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Mechanicsville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →